Assessing social and economic impact of subcutaneous mAbs in oncology

Authors

  • Americo Cicchetti ALTEMS (Alta Scuola di Economia e Management dei Sistemi Sanitari), Università Cattolica del Sacro Cuore, Roma, Italia
  • Silvia Coretti ALTEMS (Alta Scuola di Economia e Management dei Sistemi Sanitari), Università Cattolica del Sacro Cuore, Roma, Italia
  • Daniele Mascia Dipartimento di Scienze Aziendali, Università di Bologna, Italia
  • Nicola Mazzanti Roche SpA, Monza, Italia
  • Pietro Refolo Istituto di Bioetica e Medical Humanities, Facoltà di Medicina e chirurgia “A. Gemelli”, Università Cattolica del Sacro Cuore, Roma, Italia
  • Francesca R. Rolli ALTEMS (Alta Scuola di Economia e Management dei Sistemi Sanitari), Università Cattolica del Sacro Cuore, Roma, Italia
  • Filippo Rumi1 ALTEMS (Alta Scuola di Economia e Management dei Sistemi Sanitari), Università Cattolica del Sacro Cuore, Roma, Italia

DOI:

https://doi.org/10.33393/grhta.2018.443

Keywords:

Antibodies, Monoclonal, Health Technology Assessment, Regression analysis, Economic, Social impact, Patient Satisfaction

Abstract

Background: Rituximab and trastuzumab were the first monoclonal antibodies (mAbs) approved for the treatment of cancer patients. Both antibodies are administered intravenously (EV), but subcutaneous (SC) formulations have recently been developed. SC formulations proved to be as safe and effective as EV and to offer substantial benefits to the patient. Objective: The aim of this study was to provide a multidimensional assessment of the impact of rituximab and trastuzumab SC compared to the EV formulation, providing a particular focus on expected social and economic benefits for the patient. Methods: The best established HTA methods were applied to gather and organize evidence concerning the clinical, economic, organizational, social and ethical impact of SC formulations of rituximab and trastuzumab. Social aspects were investigated applying regression methods to data collected with a previous research, while the potential savings associated with the use of SC formulations were estimated by a simple economic model applying the societal perspective. Results: Patients undergoing subcutaneous formulation are significantly more satisfied with their treatment experience than those treated with intravenous formulation. Subcutaneous formulation reduces patient dosing times, with a positive effect on the care provider’s autonomy and productivity. Potential savings associated with the use of rituximab SC were estimated in € 4,050 per patient per year on average. For trastuzumab SC the estimated potential savings amounted to € 3,400 per patient per year, on average. Conclusion: Rituximab and trastuzumab are promising treatment options significantly improving patients qol and reducing the treatment burden in terms of societal costs.

Downloads

Published

2018-06-07

How to Cite

1.
Cicchetti A, Coretti S, Mascia D, Mazzanti N, Refolo P, Rolli FR, Rumi1 F. Assessing social and economic impact of subcutaneous mAbs in oncology. Grhta [Internet]. 2018 Jun. 7 [cited 2022 Oct. 1];5(1). Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/443

Issue

Section

Original Research Articles

Most read articles by the same author(s)

1 2 > >>